Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs for Americans, writes AHA Executive Vice President Tom Nickels.

Related News Articles

Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that…
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will…
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by…
Headline
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA…
Headline
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…